Drugs / Ad5 [E1-, E2b-]-CEA(6D)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01147965 | Jul 2010 → May 2017 | breast cancer, colorectal cancer, lung cancer, prostate cancer | NantCell, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5 [E1-, E2b-]-CEA(6D) | “In the present phase I/II study, cohorts of patients with advanced colorectal cancer were immunized with escalating doses of Ad5 [E1-, E2b-]-CEA(6D).” PMID 23624851 ↗ Apr 2013 |
| Known as | ETBX-011 | “The cancer vaccine is called Ad5 \[E1-, E2b-\]-CEA(6D)or ETBX-011 and is made by Etubics.” NCT01147965 ↗ |
| Modality | Vaccine | “The cancer vaccine is called Ad5 \[E1-, E2b-\]-CEA(6D)or ETBX-011 and is made by Etubics.” NCT01147965 ↗ |
| Route | Subcutaneous | “The study drug is Ad5 \[E1-, E2b-\]-CEA(6D) given by subcutaneous (SQ) injection every 3 weeks for 3 immunizations.” NCT01147965 ↗ |